Pfizer Inc. (NYSE: PFE) and BioNTech SE – ADR announced an agreement with the U.S. government Wednesday to supply an initial consignment of 100 million doses of the coronavirus vaccine the companies are developing in the event of future emergency use authorization or full approval for the shot.
US Government Deal Positive For Pfizer: Pfizer's deal is positive for the nation as well as the company, BofA Securities analyst Geoff Meacham said in a note.
The U.S. government has the optionality to acquire an additional 500 million doses the analyst said. Assuming a two-dose regimen, 600 million doses could cover over 90% of the U.S. population, he said.
For Pfizer, the vaccine news is a positive development, Meacham said.
That said, the analyst does not see the vaccine programs as being fully derisked is looking ahead to additional data as Phase 3 trials get underway.
Pfizer's Vaccine Economics: At the $20 price point implied by the U.S. government's contract value and assuming a 50-50 gross profit split between Pfizer and BioNTech, Meacham expects the vaccine to be helpful to Pfizer's P&L.
This is especially true as company contends with portfolio risks that include the adjuvant Ibrance failure, recent pipeline programs that failed to stand apart from competition and the Eliquis patent ruling, the analyst said.
Pfizer shares have added about $30 billion in value since their recent low in June, mainly on COVID-19 news. The valuation implies about 1.5 billion doses sold at the $20 price point, Meacham said.
To justify the valuation, Pfizer may have to sell about 6 billion doses at a 50% margin, according to BofA — more than the sell-side firm's assumed number of patients treated worldwide through 2030 .
PFE Rating, Price Action: Meacham maintained a Neutral rating on Pfizer with a $38 price target.
At last check, Pfizer shares were down 0.18% at $38.49.
Related Links:
Intel, Texas Instruments To Kickstart Chip Earnings With 'Better-Than-Feared' Results
Nvidia Analysts See Multibillion-Dollar Opportunity In Automated Driving Deal With Mercedes-Benz
Latest Ratings for PFE
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jun 2020 | SVB Leerink | Initiates Coverage On | Market Perform | |
| Jun 2020 | JP Morgan | Maintains | Neutral | |
| Apr 2020 | Barclays | Maintains | Equal-Weight |
View More Analyst Ratings for PFE
View the Latest Analyst Ratings
See more from Benzinga
- Moderna Analyst Says Odds Are Good For COVID-19 Vaccine Approval, But Valuation Overcooked
- Novavax Shares Rebound Amid Coronavirus Vaccine Update
© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Health - Latest - Google News
July 24, 2020 at 01:57AM
https://ift.tt/2WSi0Rd
Pfizer Analyst Says COVID-19-Driven Rally Not Backed By Vaccine Economics - Yahoo Finance
Health - Latest - Google News
https://ift.tt/2zrj9Ud
https://ift.tt/3dmOvwM
Bagikan Berita Ini
0 Response to "Pfizer Analyst Says COVID-19-Driven Rally Not Backed By Vaccine Economics - Yahoo Finance"
Post a Comment